News

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

This interview segment with Irvine highlighted his team’s data presented at EADV regarding children 6-11 years with atopic dermatitis on dupilumab.

Nijhoff discusses the positive results of the first portion of the phase 1/2/3 trial and its implications for the underserved T1D patient population.

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

In this interview, improvements observed in children 6-11 years with severe atopic dermatitis following dupilumab use were spotlighted.

Mellinger joins Liver Lineup to discuss current shortcomings in ALD diagnosis and care, the importance of addressing underlying alcohol use disorder, and more.

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

New research links sleep-related leg movements to a higher risk of diabetes.

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Roche’s Elecsys pTau181 blood test helps primary care clinicians rule out Alzheimer’s amyloid pathology in patients with cognitive symptoms.

Oticara’s intranasal steroid cream meets primary endpoints in phase 2 trial, providing rapid, durable symptom relief for post-surgical chronic rhinosinusitis.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.

Explore how healthcare resilience and sustainability intertwine, addressing climate challenges while enhancing patient care and community health outcomes.

A 9-year real-world study found allergen immunotherapy reduced medication use and asthma flare-ups, showing lasting control of allergic rhinitis.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

In this segment of her EADV interview, Markowitz highlights 3-D imaging data from the DISCOVER study on dupilumab (Dupixent) and atopic dermatitis in skin of color.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Results from the phase 3 trial show consistent reductions in annualized bleeding rate after 12 months of once-weekly treatment.

This EADV interview features a discussion of data from the DISCOVER study on the effects of dupilumab (Dupixent) on atopic dermatitis in skin of color.

New research links early baby formula feeding to increased risks of peanut and multiple food allergies, highlighting the importance of colostrum.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.